Global Down Syndrome

Winter 2016

Issue link: https://viewer.e-digitaledition.com/i/657802

Contents of this Issue

Navigation

Page 8 of 31

CONTINUED ON PAGE 11 THE NATIONAL INSTITUTES OF HEALTH (NIH) BIOMARKERS OF ALZHEIMER'S DISEASE IN ADULTS WITH DOWN SYNDROME INITIATIVE — TWO WOMEN'S COLLABORATION AND DEDICATION HELPED MAKE IT ALL POSSIBLE. MELISSA A. PARISI, M.D., Ph.D., is Chief of the Intellectual and Developmental Disabilities Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). A pediatric geneticist by training, Dr. Parisi earned a medical degree and a doctoral degree in developmental biology from Stanford University. After training in medical genetics, she was Assistant Professor at the University of Washington and Seattle Children's Hospital. Dr. Parisi was drawn to the field of pediatric genetics by her desire to understand why some children have differences in growth and development and an interest in helping children with genetic conditions live full and fulfilling lives. She has dedicated her career to researching Down syndrome as well as other genetic conditions. Laurie Ryan, Ph.D., is Chief of the Dementias of Aging Branch in the Division of Neuroscience at the National Institute on Aging (NIA). Dr. Ryan completed her doctorate in clinical said Laurie Ryan, Ph.D., Chief of the Dementias of Aging Branch in the Division of Neuroscience at the National Institute on Aging. "Because we're further along in biomarker discovery, applying these techniques to research Alzheimer's disease in people with Down syndrome is a natural next step." THE STUDIES AT A GLANCE The NIA and NICHD will provide the estimated $37 million to two research teams over the next five years as part of a new project called the NIH Biomarkers of Alzheimer's Disease in Adults with Down Syndrome Initiative. Benjamin Handen, Ph.D., an investigator affiliated with the Department of Psychiatry at the University of Pittsburgh, and Nicole Schupf, Ph.D., an investigator affiliated with Columbia University Medical Center, will each lead a research team. Through their research, Drs. Handen and Schupf hope to standardize research methodology and create a network of data Champions of Progress and tissue samples that will inform future studies. They also hope to identify and track biomarkers that signal Alzheimer's disease development using information generated through the following: • PET scans, which provide a clear picture of how organs and tissues in the body function. PET scans help detect cancer, infections, and changes in organ function, and the researchers will use these scans to track the levels of certain molecules in the brain and look for hallmarks of Alzheimer's disease, such as amyloid plaque deposits and tau tangles. • Magnetic resonance imaging (MRI), which will be used to track the size, or volume, of the brain and brain function. • Blood tests that will track biomarkers, such as cholesterol levels, and look for genes that may raise someone's risk of Alzheimer's disease or, conversely, offer protection against the accumulation of Alzheimer's disease- related amyloid plaque and tau tangles. Because so many people with Down syndrome develop plaques and tangles in the brain without developing dementia, these researchers hope to identify blood biomarkers, including potentially genetic changes, that predict who will develop dementia among both the Down syndrome and the typical populations. "Interestingly, typical people with Alzheimer's disease have developed many trisomy or Down syndrome-like cells throughout their bodies, including the blood and the brain. This mechanistic link between the two disorders has many important implications," said Huntington Potter, Ph.D., Director of Alzheimer's Research at the Linda Crnic Institute for Down Syndrome. "Down syndrome offers a window into the study of Alzheimer's disease that is unparalleled," Dr. Potter added. "The NIH's recognition of the importance of investigating Alzheimer's disease in this special population represents a very big advancement in furthering the science behind Alzheimer's disease development." GLOBALDOWNSYNDROME.ORG 9

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - Winter 2016